Neurocrine Revenue Jumps 41% as Product Sales Pass $1 Billion for the First Time
The company raised its full-year INGREZZA sales guide and trimmed its spending outlook — while standard accounting, weighed down by an acquisition and an investment loss, shows a smaller profit than a year ago.